Tag: Intracs em

New partnership: joimax® joins forces with JAPAN MEDICALNEXT CO., LTD.

Posted on by Antonio Berlen

Karlsruhe (GER), 16 June 2020
 joimax®, the German-based market leader in technologies and training methods for full-endoscopic and minimally invasive spinal surgery, is starting as of now a new partnership in Japan. The distributor JMC- JAPAN MEDICALNEXT CO., LTD. and joimax® are pursuing a long-term sales cooperation that will result in an extensive distribution agreement for the entire Japanese market.

joimax® joins forces with JAPAN MEDICALNEXT CO., LTD.

joimax® is looking forward to working with a partner strong as JMC, says joimax® Founder and CEO Wolfgang Ries and adds, “a company that has the necessary personnel, expertise, as well as the corresponding specialization and penetration of the market”. Masayuki Yoshimura, President and CEO of JMC, explains, “We are very excited to partner with joimax®. With our shared vision for advancing the field of minimum invasive spinal surgery, we are looking forward to introducing the globally recognized joimax® products in Japan”. Thus, joimax® strengthens its sales activities in Japan and enters into another important partnership in Asia.

JAPAN MEDICALNEXT CO., LTD. founded in 1992 is located in Osaka, Japan. With 314 employees at its locations and an Orthopedics Division that will focus on joimax® products, the company is a wholly-owned entity of MC Healthcare, Inc. (subsidiary of Mitsubishi Corporation) and prominent supplier of medical devices in Japan.

joimax® Celebrates Resounding Success at the German Spine Society (DWG) Convention 2019

Posted on by Antonio Berlen

Karlsruhe (GER) / Irvine, CA – December 3, 2019 – joimax®, the Germany-based market leader of technologies and training methods for full-endoscopic minimally-invasive spinal surgery, celebrated resounding success at this year’s German Spine Society (DWG), held November 28 to 30 in Munich, Germany. joimax® presented
its newest product innovations and hosted several informative sessions to rave reviews, exceeding expectations.

Spine Award 2019, joimax navigation system, Intracs, endoscopic spine surgery

Among the products showcased was a new member of the joimax® TESSYS® family, TESSYS® Thx, a system specifically developed for the symptomatic thoracic deherniation and decompression treatment. Surgeries utilizing TESSYS® Thx can avoid complications often associated with traditional open and microsurgical approaches, such as significant muscle damage, bony resection, and morbidities. joimax® also presented Intracs®em, the first electromagnetic system for endoscopic spine applications that can navigate instruments directly at the tip, if required. This navigation system combines side and AP images of the C-arm with the CT axial scan, providing surgeons with meaningful views of the target region. Intracs® em received its CE mark earlier this year and has been successful throughout Europe and Asia. FDA approval is pending; expected by year’s end. Moreover, joimax® presented its Endoscopic Spine Academy ESPINEA®. This modular training program, divided into a Pre-Clinical Training with anatomical models, endoscopic tools, and simulators, and a Clinical Training, part of the joimax® CM3 program consisting of visitation, hands-on workshops, and the first surgery, offers surgeons specific support to optimize and significantly shorten the individual learning curve.

Additional highlights included, the daily Meet the Expert Sessions, a Needle Placement Challenge with attractive prizes, and a lunch symposium on “Endoscopy in the Course of Time”.

joimax® CEO and Founder Wolfgang Ries states, “Our unmatched attention to the needs of surgeons enables us to be one step ahead. The reception of our products at this convention reinforced our commitment to endoscopy and underscored the importance of showcasing innovative products such as Intracs®em.  By participating in national and international spine congresses, we are able to achieve broad market penetration for the benefit of the patient”.

joimax® Wins 2019 Spine Technology Award for its Integrated Navigation Tracking & Control System, Intracs®em and Exhibits at NASS

Posted on by Antonio Berlen

Irvine, CA – joimax®, a leading developer and marketer of complete systems for endoscopic minimally invasive spinal surgery, is pleased to announce they’ve won a 2019 Orthopedics this Week Spine Technology Award for their new Integrated Navigation Tracking & Control System, Intracs®em. joimax® will be recognized with the award during the annual North American Spine Society Meeting (NASS), taking place September 25-28 in Chicago.

joimax® is heavily involved in this year’s NASS program. On Wednesday, September 25, they will host three stations at the new, hands-on, full-day course, NASS/Neurospine Endoscopic Spinal Surgery Symposium and Cadaver Workshop, co-sponsored by KOMISS. Moreover, joimax® will present the latest technologies at their booth, No. 3416, including Intracs®em, the first electromagnetic system for endoscopic spine applications. Earlier this year, Intracs®em received its CE mark and is already very successful within Europe and Asia. It is pending FDA clearance; expected before year end.

joimax® is also presenting ESPINEA®, Endoscopic Spine Academy, with its complete joimax® endoscopic education curriculum, which will play a crucial role in educating the next generation of endoscopic spine surgeons. Additional highlights in the booth will be the 4K Endoscopic tower and its optimal solution for endoscopic spinal surgery, as well as the latest 3D-printed EndoLIF® Cage family, consisting of the EndoLIF® O/On-Cage, DoubleWedge-Cage and Delta- Cage.

Wolfgang Ries, joimax® CEO and Founder states, “We are excited about the most recent developments within the US market. We are experiencing a great movement towards joimax® procedures, such as TESSYS® and iLESSYS®, from academics as well as private institutions. With our recently established ESPINEA® and the support from societies such as NASS, we believe we are at the tipping point where joimax® endoscopic spine surgery will become the gold standard of treatment in the US market.”